The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 06, 2024

Filed:

Jul. 15, 2021
Applicant:

University of Notre Dame Du Lac, South Bend, IN (US);

Inventors:

Mayland Chang, Granger, IN (US);

Shahriar Mobashery, Granger, IN (US);

Derong Ding, South Bend, IN (US);

Assignee:

University of Notre Dame du Lac, South Bend, IN (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 271/06 (2006.01); A61K 9/00 (2006.01); A61K 9/12 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61L 9/12 (2006.01); A61P 31/04 (2006.01); C07D 413/04 (2006.01); C07D 413/10 (2006.01); C07D 413/12 (2006.01);
U.S. Cl.
CPC ...
C07D 271/06 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/12 (2013.01); A61K 9/2027 (2013.01); A61K 9/2059 (2013.01); A61K 9/4866 (2013.01); A61P 31/04 (2018.01); C07D 413/04 (2013.01); C07D 413/10 (2013.01); C07D 413/12 (2013.01);
Abstract

infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.


Find Patent Forward Citations

Loading…